非酒精性脂肪性肝炎和心理健康背景下的肥胖治疗
Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health.
作者信息
Sharma Aadi, Albhaisi Somaya, Sanyal Arun J
机构信息
University of Virginia Charlottesville Virginia USA.
Department of Internal Medicine Virginia Commonwealth University Richmond Virginia USA.
出版信息
Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):48-51. doi: 10.1002/cld.1219. eCollection 2022 Aug.
Abstract
Content available: Audio Recording.
摘要
提供的内容
录音。
相似文献
1
Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health.非酒精性脂肪性肝炎和心理健康背景下的肥胖治疗
Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):48-51. doi: 10.1002/cld.1219. eCollection 2022 Aug.
2
INFLUENCE OF OXIDATIVE STRESS AND OBESITY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS.氧化应激和肥胖对非酒精性脂肪性肝炎患者的影响
Arq Gastroenterol. 2015 Jul-Sep;52(3):228-33. doi: 10.1590/S0004-28032015000300014.
3
Behavioral health disorders related to nonalcoholic steatohepatitis.与非酒精性脂肪性肝炎相关的行为健康障碍。
Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):43-47. doi: 10.1002/cld.1211. eCollection 2022 Aug.
4
Nonalcoholic fatty liver disease: a systematic review.非酒精性脂肪性肝病：系统评价。
JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.
5
The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity.左旋肉碱治疗非酒精性脂肪性肝炎伴肥胖患者的疗效。
Lipids Health Dis. 2023 Jul 12;22(1):101. doi: 10.1186/s12944-023-01867-3.
6
PRO: Should patients with nonalcoholic steatohepatitis fibrosis undergo bariatric surgery as primary treatment?专业问题：非酒精性脂肪性肝炎纤维化患者应接受减重手术作为主要治疗方法吗？
Clin Liver Dis (Hoboken). 2022 Jul 16;20(1):5-8. doi: 10.1002/cld.1224. eCollection 2022 Jul.
7
CON: Should patients with nonalcoholic steatohepatitis fibrosis undergo bariatric surgery as a primary treatment?反对观点：非酒精性脂肪性肝炎纤维化患者是否应将减肥手术作为主要治疗方法？
Clin Liver Dis (Hoboken). 2022 Jul 22;20(1):9-12. doi: 10.1002/cld.1226. eCollection 2022 Jul.
8
Nonalcoholic steatohepatitis in Asia-Oceania.亚太地区的非酒精性脂肪性肝炎。
Hepatol Res. 2005 Oct;33(2):64-7. doi: 10.1016/j.hepres.2005.09.005. Epub 2005 Oct 26.
9
Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.肝移植治疗非酒精性脂肪性肝炎：复发的病理生理学和临床挑战。
Dig Dis Sci. 2019 Dec;64(12):3413-3430. doi: 10.1007/s10620-019-05716-1. Epub 2019 Jul 16.
10
Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds.家族性非酒精性脂肪性肝炎和隐源性肝硬化
Am J Med. 2000 Jan;108(1):9-13. doi: 10.1016/s0002-9343(99)00315-0.
引用本文的文献
1
A narrative review of approved and emerging anti-obesity medications.已批准和新出现的抗肥胖药物的叙述性综述。
Saudi Pharm J. 2023 Oct;31(10):101757. doi: 10.1016/j.jsps.2023.101757. Epub 2023 Aug 24.
本文引用的文献
1
Behavioral health disorders related to nonalcoholic steatohepatitis.与非酒精性脂肪性肝炎相关的行为健康障碍。
Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):43-47. doi: 10.1002/cld.1211. eCollection 2022 Aug.
2
Diet, Obesity, and Depression: A Systematic Review.饮食、肥胖与抑郁：一项系统综述。
J Pers Med. 2021 Mar 3;11(3):176. doi: 10.3390/jpm11030176.
3
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.当前及即将上市的抗肥胖药物综合综述
Diabetes Metab J. 2020 Dec;44(6):802-818. doi: 10.4093/dmj.2020.0258. Epub 2020 Dec 23.
4
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
5
The limits and challenges of antiobesity pharmacotherapy.抗肥胖药物治疗的局限性和挑战。
Expert Opin Pharmacother. 2020 Aug;21(11):1319-1328. doi: 10.1080/14656566.2020.1748599. Epub 2020 Apr 15.
6
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?内分泌疾病管理：GLP-1 激动剂在治疗 2 型糖尿病方面都一样吗？
Eur J Endocrinol. 2019 Dec;181(6):R211-R234. doi: 10.1530/EJE-19-0566.
7
Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects.肥胖的药物治疗：作用机制及心脏代谢效应
Ann Transl Med. 2019 Aug;7(16):393. doi: 10.21037/atm.2019.07.27.
8
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).在二型糖尿病患者中，每周一次司美格鲁肽 1.0mg 与每日一次利拉鲁肽 1.2mg 作为 1-3 种口服抗糖尿病药物的附加疗法的疗效和安全性 (SUSTAIN 10)。
Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 2019 Sep 17.
9
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.司美格鲁肽对 2 型糖尿病和/或肥胖患者肝酶和炎症标志物的影响。
Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. Epub 2019 Jun 10.
10
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.在治疗 2 型糖尿病方面，每周一次皮下注射司美格鲁肽的疗效、安全性和心血管结局比较：来自 SUSTAIN 1-7 试验的结果。
Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4.
Zotero 插件